$333.78+5.53% · 3M
Moving avg
1W+2.25%
1M-4.70%
3M+8.98%
6M+20.74%
YTD+35.18%
1Y+122.03%
3Y+177.60%
5Y+518.35%
52-week range
$130.5081% of range$382.53
Company health
Value0/6
Growth6/6
Profitability6/6
Health5/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Strong 53% net margin
- High return on equity (1925%)
- Revenue compounding 624% a year
- Net cash on the balance sheet
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$9.84B
Enterprise value
$9.17B
P/E ratio (TTM)
42.30x
P/S ratio (TTM)
23.16x
EV/EBITDA
45.71x
Per share & returns
EPS (TTM)
$7.68
Dividend yield
0.00%
Beta (1Y)
0.50
30-day change
-4.70%
Trading
Volume (24h)
40.10K
Previous close
$332.86
Shares outstanding
29.48M
About Krystal Biotech, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
KRYS
Krystal Biotech, Inc. is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker KRYS.
Frequently asked questions
What is Krystal Biotech, Inc.'s market cap?
Krystal Biotech, Inc. (KRYS) has a market capitalization of $9.84B.
What is Krystal Biotech, Inc.'s P/E ratio?
Krystal Biotech, Inc. trades at a price-to-earnings (P/E) ratio of 42.30.
What exchange does KRYS trade on?
KRYS trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,216.03-0.35%
$1.15T cap
Johnson & JohnsonJNJ
$261.33+0.18%
$629.78B cap
AbbVie Inc.ABBV
$250.78+0.81%
$443.08B cap
UnitedHealth Group IncorporatedUNH
$402.12-0.86%
$365.18B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$354.73B cap
Merck & Co., Inc.MRK
$134.53+1.21%
$332.26B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.30B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.01B cap